Search hospitals > Nebraska > Omaha

Alegent Health Immanuel Medical Center

Claim this profile
Omaha, Nebraska 68122
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
342 reported clinical trials
3 medical researchers
Photo of Alegent Health Immanuel Medical Center in OmahaPhoto of Alegent Health Immanuel Medical Center in Omaha

Summary

Alegent Health Immanuel Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Alegent Health Immanuel Medical Center is involved with conducting 342 clinical trials across 444 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.

Area of expertise

1Cancer
Global Leader
Alegent Health Immanuel Medical Center has run 103 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Alegent Health Immanuel Medical Center has run 73 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
HER2 negative

Top PIs

Clinical Trials running at Alegent Health Immanuel Medical Center

Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Prostate Cancer
Pancreatic Cancer
Multiple Myeloma
Adenocarcinoma
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Alegent Health Immanuel Medical Center?
Alegent Health Immanuel Medical Center is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Alegent Health Immanuel Medical Center is involved with conducting 342 clinical trials across 444 conditions. There are 3 research doctors associated with this hospital, such as Richard L. Deming, Shahzad Siddique, and Mehmet S. Copur.
Where is Alegent Health Immanuel Medical Center located?
**Alegent Health Immanuel Medical Center - Omaha, NE** - **Address:** 6901 N 72nd St, Omaha, NE 68122 - **Public Transport:** Bus stop at Entrance A & Newport Ave NE, approximately a 4-minute walk to the hospital. - **Driving Directions:** Recommended to use Waze for accurate navigation.
Who should I call to ask about financial aid or insurance network?
**Alegent Health Immanuel Medical Center Financial and Insurance Information:** - **Financial Assistance:** Patients in need can apply for financial support through the Financial Assistance Program. Visit the Emanuel Medical Center's website for application details. - **Insurance Inquiries:** Contact the Alegent Creighton Health Business Office for insurance-related questions. They manage insurance matters for all Alegent Health facilities.
What insurance does Alegent Health Immanuel Medical Center accept?
Alegent Health Immanuel Medical Center accepts a wide range of insurance plans, including but not limited to Aetna Medicare, AgeRight Advantage, Atrio Medicare, and Cigna Medicare Advantage. The center is also part of the Aetna Whole Health - CHI Health Accountable Care Network, offering plans with the full Aetna network and a High Deductible Health Plan (HDHP) option with a Health Savings Account (HSA). For detailed information on accepted insurance plans, contacting the hospital directly or consulting with specific insurance providers is advised.
What awards or recognition has Alegent Health Immanuel Medical Center received?
Alegent Health Immanuel Medical Center, located in Omaha, Nebraska, is recognized for its high performance in two adult procedures and conditions. It is also accredited by The Joint Commission, meeting full standards compliance.